Q1 FY27 Results: Standalone Revenue Falls to Rs 9.81L, Loss at Rs 2.19 Cr

Revenue DeclinePat NegativeResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.4%Reaction day

₹6.34

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-5.4% vs market

Pharmaceuticals peers, median of 166sector-0.4%-5.0% vs sector

On the reaction day the stock moved 5.4 pts less than Nifty Microcap 250 and 5.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.4+0.1-5.4-0.4-5.0

Next day

-7.3+0.2-7.5-0.3-6.9

-7.3+0.6-7.8-0.5-6.7

-11.5-0.0-11.5-1.3-10.2

-7.7+0.5-8.2-0.8-6.9

-9.3+0.8-10.1-0.4-8.9

-10.3+0.6-10.8-0.9-9.4

15d

-5.4+1.3-6.6+0.0-5.4

-5.7-1.4-4.3-0.1-5.6

-3.9-0.6-3.4-2.6-1.3

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Decipher Labs Q1 FY27 (quarter ended 30 June 2026): Standalone revenue was Rs 9.81 lakhs, sharply down from Rs 84.65 lakhs in Q1 FY26, with a loss of Rs 7.93 lakhs. Consolidated revenue was Rs 241.39 lakhs versus Rs 292.37 lakhs year on year and net loss narrowed to Rs 218.57 lakhs from Rs 342.67 lakhs year on year. Auditor Ramanatham and Rao issued an unqualified limited review report. Board also appointed Mr Bhupendralal Waghray as Independent Director for five years.

Likely market impact

Sharp standalone revenue drop and continued losses signal ongoing business weakness. Recovery depends on consulting and pharma segments turning around.